Compare Duolingo Inc (DUOL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Duolingo Inc trades at $150.5 (market cap $7.08B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18× Duolingo Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DUOL | VRTX | |
|---|---|---|
Market Cap | $7.08B | $127.55B |
Volume | 729,171 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $341.08 | $557.96 |
52-Week Low | $90.03 | $407.37 |
Typical Hold Time | 137 Days | 120 Days |
Enterprise Value | $5.85B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.72, up 2.42% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $369M in 2022 to $1.04B in 2025 and net income surging to $414M. Recent earnings consistently beat expectations, though Q3 2026 results are pending. Analyst consensus is mixed with 37.5% buy ratings but a $140.63 price target below current levels. Operating cash flow reached $388M in 2025, supporting continued investment in user growth and AI capabilities.
Duolingo presents growth potential through AI-driven expansion and strong user metrics, but faces risks from insider selling and valuation concerns. The stock's current price exceeds analyst consensus, suggesting limited near-term upside. Key opportunities include market expansion beyond language learning, while risks involve competitive pressures and execution on monetization strategies.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
